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doi:10.1016/j.kjms.2011.10.009Abstract The aim of this study was to evaluate the clinical and pathologic features of a rare
tumor (adenoma malignum, AM). We retrospectively analyzed the medical records of 18
patients diagnosed with AM at a single institute between March 1992 and November 2009.
The median age of the patients was 45.8 years (range 29e76 years) and the mean follow-up
period was 49.2 months (range 4e168 months). A preoperative cytologic diagnosis (Papanico-
laou smear) of AM was made in 22.2% (4/18) of the cases. Ten (55.6%) of the 18 patients were
misdiagnosed with other benign diseases and underwent hysterectomies, which confirmed AM.
Sixteen patients with AM were in the early stage (IB1, 11/18; IB2, 5/18) and the other two
patients were in the advanced stage. Fourteen of 18 patients (77.8%) had pure AM alone.
Adjuvant therapy was administered to eight of the patients (44.4%) with AM. The recurrence
rate was zero, but the disease progressed in two of the patients (11.1%), who died of the
disease. The 5-year survival rate was 88.8%. A cytological diagnosis of AM based on a Papanico-
laou smear is rarely made; a deep biopsy (cone biopsy or endocervical curettage) is necessary
to diagnose this rare tumor preoperatively when there is any clinical suspicion of AM.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Obstetrics and Gynecology,
f Ulsan College of Medicine,
2-714, Korea.
il.net (Y.-S. Kwon).
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Adenoma malignum (AM) is a rare variant of adenocarci-
noma of the uterine cervix. AM comprises 1e3% of all
cervical adenocarcinomas [1]. Unlike typical cervicaled.
Table 1 Preoperative clinicopathological characteristics.
Mean age (y) 45.8 (range 29e76)
Most common symptom
Profuse vaginal discharge 8/18 (44.4%)
Vaginal bleeding 6/18 (33.3%)
Other 4/18 (22.2%)
Cytology
Negative 14/18 (77.7%)
Abnormal findings 4/18 (22.2%)
Adenocarcinoma 2
Atypical squamous cells,
cannot rule out a high-grade lesion
1
Low-grade squamous
intraepithelial lesions
1
Biopsy tools
Cone 5/18 (27.8%)
Dilatation and curettage 4/18 (22.2%)
PeutzeJeghers syndrome
Yes 2/18 (11.1%)
No 16/18 (88.9%)
Preoperative diagnosis
Yes 8/18 (44.4%)
No 10/18 (55.6%)
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than an exophytic growth pattern. Another characteristic
of AM is that it mimics multiple nabothian cysts as a benign-
appearing tumor. In addition, the screening method for
normal uterine cervical cancer has occasionally been used
to diagnose AM. These findings make preoperative diagnosis
of AM difficult and can result in surgery being performed
based on misdiagnosis. The final diagnosis of AM is often
determined from surgical specimens.
AM of the uterine cervix is so rare that the real nature
and clinical course have not been fully clarified. In addi-
tion, standard treatment, including surgery and adjuvant
therapy, is not well documented.
In the present study, all of the patients underwent
surgery and follow up in a single institute. The current
paper focuses on the clinicopathologic aspects of AM, a very
rare type of cervical cancer.
Materials and methods
Eighteen patients diagnosed with AM of the uterine cervix
between March 1992 and November 2009 were identified
from the medical records of Cheil General Hospital and
Women’s Healthcare Center. The medical records were
analyzed for information on demographic characteristics,
surgical findings, and clinical outcomes.
The pathologic classification of cervical adenocarcinoma
was carried out according to the 1994 WHO classification
[2]. The histopathologic definition and characteristic
features of AM are as follows: (1) a highly differentiated
mucinous adenocarcinoma in which most of the glands are
impossible to distinguish histologically from normal endo-
cervical glands; (2) cytologically bland glands that vary in
size and shape; (3) increased mitotic activity; (4) hyper-
plastic appearance of the glands at the surface; and (5) an
increased number of glands positioned deeper than the
lower level of the normal endocervical glands.
The criteria of the International Federation for Obstet-
rics and Gynecology (FIGO) were applied to stage the
tumors. The histologic grading was based on the architec-
tural features of the tumors, classified as follows: grade 1,
well-differentiated tumor; grade 2, moderately differenti-
ated tumor; and grade 3, poorly differentiated tumor.
Surgery was the first treatment with or without adjuvant
therapy for all patients. The adjuvant therapy protocol
used was divided into three types, concurrent chemo-
radiotherapy (CCRT), radiotherapy alone, or chemotherapy
alone.
Kaplan-Meier curves were used to calculate the mean
overall survival (OS). The Statistical Package for Social
Science (SPSS, Inc., Chicago, IL, USA) was used for statis-
tical analysis. A p value <0.05 was considered significant.
Results
The mean age of the entire population was 45.8 years
(range 29e76 years). The major symptoms at the time of
diagnosis were profuse vaginal discharge (8/18, 44.4%) and
vaginal bleeding (6/18, 33.3%). Cytologic screening of the
uterine cervix revealed negative cytology results in 14 cases
(77.7%) and abnormal findings in four cases (22.2%). Two ofthe four cases with abnormal cytology were shown to be
adenocarcinoma. Further evaluation tools included cone
biopsy and dilatation and curettage (D&C) of the uterine
endometrium. The total preoperative diagnosis rate was
44.4% (8/18). There were two cases of AM combined with
PeutzeJeghers syndrome. Table 1 lists demographic data
for the 18 patients.
The mean tumor diameter was 3.61 cm (range
1.0e7.5 cm). Sixteen cases were classified as stage IB and
two cases were classified as advanced stage according to
the 1985 FIGO staging system. A type III radical hysterec-
tomy with pelvic lymph node dissection (PLND) was per-
formed in eight cases (44.4%) and 10 patients underwent
a type I hysterectomy with or without PLND (5 with PLND
and 5 without PLND). Among the 13 cases with PLND, lymph
node metastasis was detected in three cases, two of which
were advanced. One case with a stage IB1 tumor had
co-occurrence of moderately differentiated mucinous
adenocarcinoma. Fourteen cases (77.8%) had AM alone and
four cases (22.2%) had AM combined with other types of
adenocarcinoma. Lymph-vascular space invasion (LVSI) was
positive in five cases; four cases had positive LVSI with
other adenocarcinoma (Table 2).
Eight patients underwent adjuvant therapy after the
initial surgical treatment. Four, three, and one cases
underwent CCRT, radiotherapy alone, and chemotherapy
alone, respectively. Two advanced cases with treatment
failure died of the disease. In the first case (stage IV with
positive metastasis to the para-aortic lymph nodes), the
patient received CCRT with paclitaxel and carboplatin. The
patient declined further treatment and her follow-up was
lost for 8 months. On follow-up evaluation, the patient
had multiple peritoneal metastases and bilateral hydro-
nephrosis; thus, she was not eligible for salvage treatment.
Table 2 Treatment and pathology of adenoma malignum
(n Z 18).
Stage
IB1 11/18 (61.1%)
IB2 5/18 (27.8%)
III 1/18 (5.6%)
IV 1/18 (5.6%)
Mean tumor diameter (cm) 3.61 (range 1.0e7.5)
Operation type
Type I hysterectomy 5/18 (27.8%)
Type I hysterectomy with PLND 5/18 (27.8%)
Type III hysterectomy with PLND 8/18 (44.4%)
Co-occurrence of other adenocarcinoma
Adenoma malignum alone 14/18 (77.8%)
Mixed type 4/18 (22.2%)
Adjuvant therapy
Yes 8/18 (44.4%)
No 10/18 (55.6%)
PLND Z pelvic lymph node dissection.
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neoadjuvant CCRT with paclitaxel and carboplatin. A
follow-up imaging study showed progression of the disease. A
type I hysterectomy with unilateral salpingo-oophorectomy
was performed and the debulking rate was suboptimal owing
to a radiation-induced frozen pelvis and multiple cancer
invasion. The patient died of disease progression on the 18th
post-operative day.
The other 16 patients survived without recurrence. The
mean follow-up period was 49.2 months (range 4e168
months).Figure 1. Transvaginal ultrasonography axial scan showing
a multilocular cystic mass in the deep cervical portion. The
tumor was histologically confirmed to be adenoma malignum
after a hysterectomy.Discussion
AM of the uterine cervix was first described by Gusserow in
1870 [3]. In 1963, McKelvey and Goodlin reported five AM
cases [4]. In 1975, the term minimal deviation adenocar-
cinoma was proposed by Silverberg and Hurt [5] for tumors
with good differentiation and a good prognosis. Recently,
a few cases of complicated AM have been described.
However, there are few reports with analysis of a relatively
large cohort. To date, the largest analysis of AM was
reported by Gilks et al. [6]. The extreme rarity of AM of the
uterine cervix suggests that there is no accurate prognosis
or standard treatment.
The major symptoms of AM are abnormal vaginal
discharge and vaginal bleeding. The symptoms caused by
secretion of the tumor itself are the most characteristic
symptoms in patients with AM. A profuse vaginal discharge
occurred in all cases reported by Hirai et al. [6] and 11 of 26
cases reported by Gilks et al. [7]. In the present study,
77.7% of patients had the major AM symptoms (profuse
vaginal discharge in 8/18 and abnormal vaginal bleeding in
6/18). When there are grossly normal vaginal and cervical
findings in patients with these major symptoms, the pres-
ence of a multi-locular cystic mass in the uterine cervix asdetected by ultrasonography can help in making a clinical
diagnosis of AM (Fig. 1).
A preoperative histologic diagnosis of AM is often diffi-
cult if the physician does not examine patients with
particular concern about this disease. The routine
screening method for a diagnosis of uterine cervical cancer
is a cytological evaluation [Papanicolaou (Pap) smear].
Because the lesion is located deep in the endocervix and AM
is an extremely rare disease, it is difficult to determine an
accurate cytological diagnosis. Hirai et al. reported that
exfoliative cytology seems to be an important diagnostic
technique for detecting this rare subtype of cervical
adenocarcinoma [7]. However, several studies concluded
that a Pap smear is not as important in detecting AM
because of the minimal cytologic deviation [1,6,8]. This
study revealed a negative Pap smear in 14 cases (77.7%) and
two cases of adenocarcinoma on the Pap smear were found
to be a co-occurrence of an AM and an endocervical-type
adenocarcinoma of the uterine cervix. In the present
study, eight patients had a cervical conization or D&C (one
patient underwent both conization and D&C). All eight
cases were diagnosed preoperatively with AM.
McGowan et al. reported that PeutzeJeghers syndrome
may sometimes be complicated by AM [9]. In the present
series, there were two cases (11.1%) of PeutzeJeghers
syndrome for women aged 29 and 31 years. Both patients
were treated for bowel problems before AM was detected.
The overall incidence of carcinoma in these patients varies
from 20% to 50%, and the cumulative risk of cervical cancer
occurring between the ages of 15 and64 years is 10%
[10,11]. One case was advanced stage IV and the patient
died of the disease after the initial diagnosis and surgical
treatment with CCRT. The other case was FIGO stage IB2.
This patient was given two courses of neoadjuvant
chemotherapy, followed by a laparoscopic radical hyster-
ectomy with PLND. Three courses of adjuvant chemo-
therapy were administered and no clinical evidence of
recurrence was observed during a 26-month follow-up
period. This case was previously reported [12].
The prognosis for AM is controversial. An early report
suggested an unfavorable prognosis in patients with AM [4].
Table 3 Survival outcomes.
Adjuvant therapy 8/18 (44.4%)
CCRT
Weekly cisplatin 2/8 (25.0%)
Paclitaxel and cisplatin 2/8 (25.0%)
RT alone 3/8 (37.5%)
Chemotherapy alone
(paclitaxel/cisplatin)
1/8 (12.5%)
Prognosis
Recurrence 0
Progression 2/18 (11.1%)
Death 2/18 (11.1%)
Mean follow-up (m) 49.2 (range 4e168)
CCRT Z concurrent chemoradiation therapy.
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four of five patients in their series were disease-free for at
least 3 years [5]. More recently, findings by Gilks et al. [6]
for the largest case study were in agreement with those
of McKelvey and Goodlin [4] and Kaku and Enjoji [13].
However, Hirai et al. reported that most neoplasms in these
unfavorable reports were discovered at an advanced stage
[7]. Moreover, AM tumors are often treated based on clin-
ical understaging and undertreatment, which can result in
a relatively poor prognosis. This study with a relatively
large cohort of 18 AM cases suggests that the prognosis for
these neoplasms is very good and might be consistent with
that for other forms of well-differentiated adenocarci-
nomas of the cervix. In this series, 16 of the 18 cases are
well with no clinical evidence of recurrence after a mean
follow-up period of 49.2 months. The 5-year survival rate
was 88.8% (Table 3).
The main treatment for AM is surgery. No standard
surgical treatment has been established because of its
rarity, preoperative misdiagnosis, and a scarcity of data on
surgical outcomes according to hysterectomy type. In this
series, five patients with a type I hysterectomy without
PLND all had a preoperative misdiagnosis of benign dis-
ease. The eight patients with a type III hysterectomy were
all diagnosed preoperatively with cervical malignant
neoplasms and all cases received planned surgical treat-
ment. One younger unmarried woman among the eight
patients with a preoperative diagnosis of AM underwent
a laparoscopic radical hysterectomy after receiving two
neoadjuvant chemotherapy sessions to reduce the tumor
size. The other five patients with a type I hysterectomy
with PLND were all diagnosed intra-operatively through
a frozen biopsy. These data raise the following questions:
(1) is a type III hysterectomy necessary for treating a pure
AM of FIGO stage I?; and (2) as there are few data regarding
the need for adjuvant therapy, which type of adjuvant
therapy is the best treatment?In conclusion, the prognosis for AM was found to be
better than that of ordinary cervical adenocarcinoma. A
routine cytological screening test has low power in
detecting AM. Therefore, an additional deep biopsy (cone
biopsy or endocervical curettage) is necessary to diagnose
this rare tumor preoperatively when there is any clinical
suspicion of AM, a patient has profuse vaginal discharge,
and there is a multilobular cystic mass in the uterine cervix.
Additional studies will be needed to diagnose AM correctly
and determine definitive management principles through
meta-analysis using multicenter data.References
[1] Kaminski PF, Norris HJ. Minimal deviation carcinoma
(adenoma malignum) of the cervix. Int J Gynecol Pathol 1983;
2:141e52.
[2] Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG,
Wilkinson EJ. Histological typing of female genital tract
tumours. World Health Organization. 2nd ed. Berlin: Springer-
Verlag; 1994.
[3] Gusserow ALS. Ueber sarcome des uterus. Arch Gynakol 1870;
1:240e51.
[4] McKelvey JL, Goodlin RR. Adenoma malignum of the cervix.
Cancer 1963;16:549e57.
[5] Silverberg SG, Hurt WG. Minimal deviation adenocarcinoma
("adenoma malignum") of the cervix: a reappraisal. Am J
Obstet Gynecol 1975;121:971e5.
[6] Gilks CB, Young RH, Aguirre P, DeLellis RA, Scully RE. Adenoma
malignum (minimal deviation adenocarcinoma) of the uterine
cervix. A clinicopathological and immunohistochemical anal-
ysis of 26 cases. Am J Surg Pathol 1989;13:717e29.
[7] Hirai Y, Takeshima N, Haga A, Arai Y, Akiyama F, Hasumi K. A
clinicocytopathologic study of adenoma malignum of the
uterine cervix. Gynecol Oncol 1998;70:219e23.
[8] Michael HG, Kraus FT. Minimal deviation endocervical adeno-
carcinomadclinical and histologic features, immunohistochem-
ical staining for carcinoembryonic antigen, and differentiation
from confusing benign lesions. Int J Gynecol Pathol 1984;3:
261e76.
[9] McGowan L, Young RH, Scully RE. PeutzeJeghers syndrome
with "adenoma malignum" of the cervix. A report of two cases.
Gynecol Oncol 1980;10:125e33.
[10] Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ,
Gittelsohn AM, Booker SV, et al. Increased risk of cancer in the
PeutzeJeghers syndrome. N Engl J Med 1987;316:1511e4.
[11] Entius MM, Keller JJ, Westerman AM, van Rees BP, van
Velthuysen ML, de Goeij AF, et al. Molecular genetic alter-
ations in hamartomatous polyps and carcinomas of patients
with PeutzeJeghers syndrome. J Clin Pathol 2001;54:126e31.
[12] Koo YJ, Lee JE, Hong SR, Kwon YS. Co-occurrence of an
adenoma malignum and an endocervical-type adenocarci-
noma of the uterine cervix in a woman with PeutzeJeghers
syndrome. J Gynecol Oncol 2010;21:203e6.
[13] Kaku T, Enjoji M. Extremely well-differentiated adenocarci-
noma ("adenoma malignum") of the cervix. Int J Gynecol
Pathol 1983;2:28e41.
